UP!

OCR $97.92

OCR target price
97.92
0
0
Omnicare, Inc.
Type
Subsidiary
Traded as NYSE: OCR
Industry Pharmacy
Headquarters Cincinnati, Ohio, USA
Parent CVS Health
Website http://www.omnicare.com/

Omnicare was an American company working in the health care industry, established in April 1981 as a spinoff of healthcare businesses from Chemed and W. R. Grace and Company. It is currently a pharmacy specializing in nursing homes. In 2015, Omnicare was acquired by CVS Health.

In 2012, the Federal Trade Commission (FTC) sued Omnicare to block its hostile takeover of its rival PharMerica under federal anti-trust law. The FTC alleged that the acquisition would boost drug costs and inflate Medicare expenditures by consolidating the industry and reducing price competition. PharMerica owned 97 long-term-care pharmacies, while Omnicare owned approximately 200. The merger would have given Omnicare a 57% marketshare versus two percent for its nearest, non-PharMerica rival. Because of the FTC opposition, the takeover was terminated.

In November 2009, Omnicare paid US$98,000,000 to the federal government to settle five "qui tam" (whistleblower) lawsuits and government charges that the company had paid or solicited a variety of kickbacks. The company admitted no wrongdoing. The charges included allegations that Omnicare solicited and received kickbacks from a pharmaceutical manufacturer Johnson & Johnson, in exchange for agreeing to recommend that physicians prescribe Risperdal, a Johnson & Johnson antipsychotic drug, to nursing home patients.

Starting in 2006, healthcare entrepreneur Adam B. Resnick sued Omnicare, a major supplier of drugs to nursing homes, under the False Claims Act, as well as the parties to the company's illegal kickback schemes. Omnicare allegedly paid kickbacks to nursing home operators in order to secure business, which constitutes Medicare and Medicaid fraud. Omnicare allegedly had paid $50 million to the owners (Leonard Grunstein and Rubin Schron) of the Mariner Health Care Inc. and SavaSeniorCare Administrative Services LLC nursing home chains in exchange for the right to continue providing pharmacy services to the nursing homes.

In 2010, Omnicare settled Resnick's False Claims Act suit that had been taken up by the U.S. Department of Justice by paying $19.8 million to the federal government, while Mariner and SavaSeniorCare settled for $14 million.

A second whistleblower lawsuit filed against Omnicare it by Resnick and Total Pharmacy Services V.P. Maureen Nehls related to kickbacks that were part of its 2004 acquisition of Total Pharmacy Services was settled for $17.2 million by Omnicare and $5 million by the Total Pharmacy owners. Reportedly Omnicare was set to acquire JobMinglr.com for an undisclosed sum.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS

Ratings

2015-07-24 Downgrade JPMorgan Chase & Co. Overweight to Neutral $90.00 to $98.00
2015-06-04 Downgrade Goldman Sachs Buy to Neutral $32.00 to $92.00
2015-06-04 Downgrade Goldman Sachs Group Inc. Buy to Neutral $32.00 to $92.00
2015-05-21 Downgrade Cowen and Company Outperform to Market Perform $91.00
2015-04-29 Downgrade KeyBanc Overweight
2015-04-29 Downgrade KeyCorp Overweight
2015-04-24 Downgrade RBC Capital Outperform to Sector Perform $82.00
2015-04-24 Downgrade Royal Bank Of Canada Outperform to Sector Perform $82.00
2015-04-23 Reiterated Rating Credit Suisse Outperform to Neutral $85.00 to $91.00
2015-04-23 Reiterated Rating Credit Suisse Group AG Outperform to Neutral $85.00 to $91.00
2015-03-12 Boost Price Target RBC Capital Outperform $76.00 to $82.00
2015-02-26 Reiterated Rating Cowen and Company Outperform $76.00 to $84.00
2015-01-08 Boost Price Target JPMorgan Chase & Co. Overweight $73.00 to $80.00
2015-01-08 Upgrade Barclays Equal Weight to Overweight $67.00 to $83.00
2015-01-08 Upgrade Barclays PLC Equal Weight to Overweight $67.00 to $83.00
2014-10-27 Reiterated Rating Barclays Equal Weight $66.00 to $67.00
2014-09-11 Upgrade Goldman Sachs Neutral to Buy $62.49 to $76.00
2014-07-24 Reiterated Rating JPMorgan Chase & Co. Overweight $68.00 to $73.00
2014-07-17 Initiated Coverage Barclays Equal Weight
2014-06-20 Reiterated Rating Bank of America Buy $69.00 to $73.00
2014-02-24 Boost Price Target RBC Capital Outperform $59.00 to $65.00
2014-02-20 Boost Price Target Cowen and Company $64.00 to $70.00
2014-01-08 Boost Price Target Barclays Equal Weight $60.00 to $66.00
2013-12-17 Boost Price Target Goldman Sachs $59.00 to $62.00
2013-10-03 Initiated Coverage KeyBanc Buy $66.00
2013-09-30 Boost Price Target Cowen and Company Outperform $61.00 to $64.00
2010-04-01 Upgrade UBS Neutral to Buy
2015-07-24 Downgrade JPMorgan Chase & Co. Overweight to Neutral $90.00 to $98.00
2015-06-04 Downgrade Goldman Sachs Buy to Neutral $32.00 to $92.00
2015-06-04 Downgrade Goldman Sachs Group Inc. Buy to Neutral $32.00 to $92.00
2015-05-21 Downgrade Cowen and Company Outperform to Market Perform $91.00
2015-04-29 Downgrade KeyBanc Overweight

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Figueroa John G. Chief Executive Officer 0.24%  (238992) OCR / RS /
Workman John L EVP & Chief Financial Officer 0.20%  (191075) CCP / CNMD / FSS / OCR /
Kinerk Beth A SVP - Sales 0.08%  (73649) OCR /
Stamps Jeffrey M EVP & President, LTC Ops 0.06%  (60435) OCR /
Erwin W Gary SVP - Professional Services 0.06%  (56781) OCR /
LINDELL ANDREA R 0.03%  (32297) CHE / OCR /
Stewart-Jones Priscilla EVP, Human Resources 0.03%  (25684) OCR /
Carpenter Randall A SVP and CIO 0.02%  (19072) OCR /